Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.

Literature DB >> 8359923

Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.

E Gotuzzo¹, B Butron, C Seas, M Penny, R Ruiz, G Losonsky, C F Lanata, S S Wasserman, E Salazar, J B Kaper.

Abstract

Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.

Mesh：

Substances：

Year: 1993 PMID： 8359923 PMCID： PMC281106 DOI： 10.1128/iai.61.9.3994-3997.1993

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

17 in total

1. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines.

Authors: J B Kaper; M M Levine
Journal: Res Microbiol Date: 1990 Sep-Oct Impact factor: 3.992

2. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera.

Authors: J D Clemens; F van Loon; D A Sack; J Chakraborty; M R Rao; F Ahmed; J R Harris; M R Khan; M Yunus; S Huda
Journal: J Infect Dis Date: 1991-06 Impact factor: 5.226

3. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors: M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal: Lancet Date: 1988-08-27 Impact factor: 79.321

4. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults.

Authors: S J Cryz; M M Levine; J B Kaper; E Fürer; B Althaus
Journal: Vaccine Date: 1990-12 Impact factor: 3.641

5. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors: S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal: Infect Immun Date: 1989-11 Impact factor: 3.441

6. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection.

Authors: R I Glass; A M Svennerholm; M R Khan; S Huda; M I Huq; J Holmgren
Journal: J Infect Dis Date: 1985-02 Impact factor: 5.226

Review 7. Live oral vaccines against cholera: an update.

Authors: M M Levine; J B Kaper
Journal: Vaccine Date: 1993 Impact factor: 3.641

8. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors: A S Benenson; A Saad; W H Mosley
Journal: Bull World Health Organ Date: 1968 Impact factor: 9.408

9. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients.

Authors: W H Mosley; S Ahmad; A S Benenson; A Ahmed
Journal: Bull World Health Organ Date: 1968 Impact factor: 9.408

10. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors: M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal: J Clin Microbiol Date: 1985-02 Impact factor: 5.948

32 in total

1. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors: D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal: Infect Immun Date: 1999-04 Impact factor: 3.441

2. Improving the performance of enteric vaccines in the developing world.

Authors: Andrew C Serazin; Laura A Shackelton; Christopher Wilson; Maharaj K Bhan
Journal: Nat Immunol Date: 2010-09 Impact factor: 25.606

3. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors: Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal: Clin Vaccine Immunol Date: 2013-10-30

4. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Authors: D N Taylor; C O Tacket; G Losonsky; O Castro; J Gutierrez; R Meza; J P Nataro; J B Kaper; S S Wasserman; R Edelman; M M Levine; S J Cryz
Journal: Infect Immun Date: 1997-09 Impact factor: 3.441

5. An overview of Vaxchora^TM, a live attenuated oral cholera vaccine.

Authors: Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal: Hum Vaccin Immunother Date: 2019-09-20 Impact factor: 3.452

Review 6. Performance of rotavirus vaccines in developed and developing countries.

Authors: Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal: Hum Vaccin Date: 2010-07

Review 7. Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors: Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal: Hum Vaccin Immunother Date: 2014-05-26 Impact factor: 3.452